Capricor Therapeutics (NASDAQ:CAPR) Hit With Buy Rating From Maxim Group, Analysts Expect $7.0000 Stock Price

May 17, 2018 - By Adrian Erickson

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Logo

Investors sentiment increased to 4.33 in 2017 Q4. Its up 2.53, from 1.8 in 2017Q3. It is positive, as 3 investors sold Capricor Therapeutics, Inc. shares while 0 reduced holdings. 7 funds opened positions while 6 raised stakes. 4.44 million shares or 503.95% more from 735,965 shares in 2017Q3 were reported.

Pennsylvania-based Vanguard Grp Incorporated has invested 0% in Capricor Therapeutics, Inc. (NASDAQ:CAPR). Brown Advisory accumulated 0.01% or 1.14M shares. 6,500 are owned by Bancorporation Of America Corp De. Financial Architects invested in 0% or 2,000 shares. Acadian Asset Mngmt Limited Liability Corp invested in 0% or 47,489 shares. Apriem Advsr has 0.02% invested in Capricor Therapeutics, Inc. (NASDAQ:CAPR) for 50,000 shares. Royal Bankshares Of Canada reported 232 shares or 0% of all its holdings. Northern Trust has 38,660 shares for 0% of their portfolio. Wells Fargo And Com Mn owns 35,300 shares. Deutsche National Bank & Trust Ag accumulated 3,000 shares. Perceptive Advisors Lc reported 4,000 shares. Blackrock owns 5,616 shares. Citadel Ltd Liability reported 10,009 shares. Financial Bank Of Ny Mellon, a New York-based fund reported 27,442 shares. Granite Point Mgmt Limited Partnership holds 33,750 shares or 0.01% of its portfolio.

Why Has Maxim Group Given Capricor Therapeutics (NASDAQ:CAPR) a $7.0000 Price Target

Stock analysts at Maxim Group has begun coverage on Capricor Therapeutics (NASDAQ:CAPR) with a key Buy rating. The PT for CAPR is exactly $7.0000. It indicates a possible upside of 426.32 % from company’s last stock close.

The stock increased 2.31% or $0.03 during the last trading session, reaching $1.33. About 215,459 shares traded. Capricor Therapeutics, Inc. (NASDAQ:CAPR) has declined 60.12% since May 17, 2017 and is downtrending. It has underperformed by 71.67% the S&P500.

Analysts await Capricor Therapeutics, Inc. (NASDAQ:CAPR) to report earnings on August, 9. They expect $-0.11 earnings per share, up 31.25 % or $0.05 from last year’s $-0.16 per share. After $-0.14 actual earnings per share reported by Capricor Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -21.43 % EPS growth.

Capricor Therapeutics, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of biological therapies for the treatment of diseases, with a focus on Duchenne muscular dystrophy, or DMD, and other medical conditions. The company has market cap of $38.30 million. The Company’s development stage drug candidates for cardiosphere-derived cells include CAP-1002 that is in Phase I/II clinical trial in subjects with DMD; and CAP-2003 that is in pre-clinical development for the treatment of certain cardiac and inflammatory conditions. It has a 14.78 P/E ratio.

More notable recent Capricor Therapeutics, Inc. (NASDAQ:CAPR) news were published by: Seekingalpha.com which released: “Capricor Therapeutics’ (CAPR) CEO Linda Marbán on Q1 2018 Results – Earnings Call Transcript” on May 10, 2018, also Globenewswire.com with their article: “Capricor Therapeutics to Present First Quarter 2018 Financial Results and Corporate Update on May 10” published on May 04, 2018, Streetinsider.com published: “UPDATE: Maxim Group Starts Capricor Therapeutics (CAPR) at Buy” on May 16, 2018. More interesting news about Capricor Therapeutics, Inc. (NASDAQ:CAPR) were released by: Nasdaq.com and their article: “Capricor Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update” published on May 10, 2018 as well as Nasdaq.com‘s news article titled: “Capricor to Present on Exosomes at the Plenary Session of the International Society for Cellular Therapy in Montreal” with publication date: May 03, 2018.

Capricor Therapeutics, Inc. (NASDAQ:CAPR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.